This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own
View analytic
Wednesday, June 21 • 4:00pm - 5:15pm
#370: Lessons Learned from the Sarepta Exondys 51 Approval

Sign up or log in to save this to your schedule and see who's attending!

Component Type: Forum
Level: Intermediate
CE: ACPE 1.25 Knowledge UAN: 0286-0000-17-531-L04-P; CME 1.25; IACET 1.25; RN 1.25

FDA’s approval amidst controversy of Sarepta’s Duchenne muscular dystrophy drug Exondys 51 (eteplirsen) was unprecedented in terms of the level of flexibility used to support accelerated approval in a rare disease. This session explores the unique conditions surrounding the drug’s patient-focused drug development program and its approval.

Learning Objectives

Describe circumstances surrounding the development and ultimate approval of eteplirsen; Identify how to apply lessons learned to other drug development efforts.


Shamim Ruff, MSc


A Challenging Path: Bridging Patient Needs With Regulatory Approval Requirements
Shamim Ruff, MSc

The Role of the Patient Perspective in the Approval of Exondys 51
Christine McSherry, RN

The Evolving Role of Orphan Drug and Subpart H Flexibility in Drug Approval
Alexander Varond, JD


Shamim Ruff

Senior Vice President of Regulatory Affairs and Quality, Sarepta Therapeutics

avatar for Christine McSherry

Christine McSherry

Executive Director, The Jett Foundation

Shamim Ruff

Senior Vice President of Regulatory Affairs and Quality, Sarepta Therapeutics
avatar for Alexander Varond

Alexander Varond

Associate, Goodwin Procter LLP
Alexander J. Varond works on drug development and medical devices, advertising and promotion, and enforcement issues. He counsels clients on drug development matters such as clinical trial design, REMS, orphan drug designation, formal dispute resolution, and patent and exclusivit... Read More →

Wednesday June 21, 2017 4:00pm - 5:15pm
S404bc McCormick Place 2301 South Martin Luther King Jr. Drive, Gate 4 Chicago, IL 60616